Post-ASCO Analysis: Daraxonrasib Poised to Transform Pancreatic Cancer Standard of Care — Revolution Medicines Accelerates NDA Filing

One week after the historic ASCO 2026 plenary presentation of RASolute 302, Revolution Medicines announced acceleration of its New Drug Application (NDA) filing for daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma, with priority review expected to reduce the standard 12-month review timeline significantly. The FDA's expanded access protocol, authorized within 2 days of the company's request in April 2026, has begun enrolling patients outside clinical trials. Academic oncologists and patient advocacy groups have called the RASolute 302 result — OS HR 0.40, 13.2 vs. 6.7 months median survival — a 'before-and-after moment' for pancreatic cancer analogous to imatinib's impact on CML in 2001. Key oncology societies (ASCO, NCCN) are convening expedited guideline panels to incorporate daraxonrasib into treatment algorithms ahead of formal approval. Major cancer centers are establishing dedicated RAS inhibitor programs. Daraxonrasib targets RAS(ON) mutations — the active GTP-bound form — using a mechanism distinct from the earlier KRAS G12C-selective inhibitors (sotorasib, adagrasib) which were ineffective in pancreatic cancer due to low KRAS G12C prevalence in that disease (~2% of PDAC). Daraxonrasib's pan-RAS(ON) activity covers KRAS G12D (most common in PDAC, ~40%), G12V (~20%), and other G12 variants (~20%), addressing approximately 90% of KRAS-mutant PDAC cases. Revolution Medicines is also investigating daraxonrasib in first-line pancreatic cancer and in other RAS-driven tumors including colorectal cancer and lung adenocarcinoma.